CD166 Protein & Antibody (ALCAM)

Cluster of Differentiation 166 (Activated Leukocyte Cell Adhesion Molecule)

CD166 Products

CD166 Protein, Recombinant

Molecule	Species	Description	Cat. No
CD166/ALCAM	Human	CD166/ALCAM/Fc Protein, Recombinant	10045-H03H
CD166/ALCAM	Human	CD166/ALCAM Protein, Recombinant	10045-H08H
CD166/ALCAM	Mouse	CD166/ALCAM/Fc Protein, Recombinant	50005-M03H
CD166/ALCAM	Mouse	CD166/ALCAM Protein, Recombinant	50005-M08H

CD166 Antibody

Molecule	Application	Description	Cat. No
Mouse CD166/ALCAM	WB, ELISA	Rabbit Polyclonal Antibody	50005-RP01
Mouse CD166/ALCAM	WB, ELISA	CD166/ALCAM Antibody, Rabbit PAb (Antigen Affinity Purified)	50005-RP02
Human CD166/ALCAM	WB, ELISA	CD166/ALCAM Antibody, Mouse MAb	10045-MM05
Human CD166/ALCAM	WB, ELISA	CD166 / ALCAM Antibody	10045-RP01
Human CD166/ALCAM	WB, ELISA	CD166 / ALCAM Antibody (Antigen Affinity Purified)	10045-RP02

CD166 cDNA Clone

Molecule	Species	Description	Cat. No
CD166/ALCAM	Human	Homo sapiens CD166/ALCAM cDNA Clone(NM_001627.2)	HG10045-M
CD166/ALCAM	Mouse	Mus musculus CD166/ALCAM cDNA Clone	MG50005-M
CD166/ALCAM	Rat	Rat CD166/ALCAM cDNA Clone	RG80221-G

CD166 Related Areas

Stem Cell>>Neural Stem Cell (NSC)>>Neuronal Cell Markers>>CD166/ALCAM

Stem Cell>>Mesenchymal Stem Cell (MSC)>>Osteoblast & Osteoclast Marker>>CD166/ALCAM

Stem Cell>>Mesenchymal Stem Cell (MSC)>>Mesenchymal Stem Cell Marker>>CD166/ALCAM

Cancer>>Cancer Stem Cell (CSC)>>CD166/ALCAM

Immunology>>Adaptive Immunity>>T Cell>>T Cell Migration/Adhesion>>CD166/ALCAM

Immunology>>Adhesion Molecule>> Cell Adhesion Molecule (IgSF CAM) >>CD166/ALCAM

Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Monocyte Markers>>CD166/ALCAM

Immunology>>Cluster of Differentiation>>T Cell CD Antigen>>T Cell Migration/Adhesion>>CD166/ALCAM

CD166 Alternative Names

CD166, ALCAM, AI853494, BEN, DM-GRASP, MGC27910, MuSC, SC1

CD166 Background

Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.

CD166 Related Studies

1. Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21.
2. Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43.
3. Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73.
4. Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.